For following the competition: what moved in each program, several studies read as one move.
- olutasidenib
- CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
- CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive
- + 1 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Rigel Pharmaceuticals to watchlistEvery Monday by email · turn it off any timePro · free during the beta